Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • onconaut
    Junior Member
    • Aug 2012
    • 7

    #1

    WES - how deep do you sequence your germline control

    Hello Seqers,

    we currently do WES with a mean coverage of ~120x for tumor as well as the germline samples. Since we only use the germline to help us with the somatic alteration calls I was thinking about cutting the coverage of the germline samples in half to free up some real estate on the flowcell. Does any one have experience with this?

    Thanks, O.
  • Bukowski
    Senior Member
    • Jan 2010
    • 388

    #2
    We'd normally do 50x on the normal and 100x+ on the tumour - I think that's quite a common strategy.

    Comment

    • bilyl
      Member
      • Aug 2013
      • 52

      #3
      It depends on your downstream processes. If you are simply calling SNVs then it doesn't really matter. But for other applications (eg. CNVs), many programs prefer to have similar coverage between your tumor and normal. Even if they don't require it, you are getting rid of other sources of variation (eg. by capturing the same amount of DNA in the same exome hyb reaction).

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 11:13 AM
      0 responses
      16 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, Yesterday, 10:48 AM
      0 responses
      16 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      35 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      42 views
      0 reactions
      Last Post SEQadmin2  
      Working...